ETHRIL 500 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ethril 500, and what generic alternatives are available?
Ethril 500 is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in ETHRIL 500 is erythromycin stearate. There are one hundred and three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for ETHRIL 500
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 26 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ETHRIL 500 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ETHRIL 500
US Patents and Regulatory Information for ETHRIL 500
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | ETHRIL 500 | erythromycin stearate | TABLET;ORAL | 061605-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |